Novus Therapeutics, Inc.
19900 MacArthur Blvd., Suite 550
Irvine, CA 92612
(949) 238-8090
April 2, 2020
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
|
Attn: |
Christine Westbrook |
|
|
Re: |
Novus Therapeutics, Inc. |
Registration Statement on Form S-1
Filed March 25, 2020
File No. 333-237379
Ladies and Gentlemen:
Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended, Novus Therapeutics, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-1 filed by the Company (the “Registration Statement”) be accelerated to 4:01 p.m., Eastern Standard Time, on April 3, 2020 or as soon thereafter as practicable.
[Signature page follows]
|
|
|
|
|
Very truly yours, |
||
|
|
||
|
Novus Therapeutics, Inc. |
||
|
|
|
|
|
By: |
|
/s/ Gregory J. Flesher |
|
Name: |
|
Gregory J. Flesher |
|
Title: |
|
Chief Executive Officer |
|
cc: |
Ryan A. Murr, Gibson, Dunn & Crutcher LLP |